Shah Rukh Khan, Ajay Devgn and Tiger Shroff have faced box-office pressure before. A formal regulatory notice from the Maharashtra FDA is a different kind of test — one that could reshape how Bollywood lends its face to products.
What Exactly Has the FDA Alleged?
The Maharashtra FDA has formally asked the three actors to explain their role in an ad campaign connected to a banned pan masala product. The allegation: the promotion crossed into surrogate advertising — a practice where brands use lookalike products to keep a prohibited brand visible in public.
Surrogate ads have been a grey zone in Indian marketing for years. When a brand cannot sell itself directly, it spins up an unrelated product — often a mint, mouth freshener or apparel line — to keep the name alive.
Why Surrogate Advertising Is a Legal Flashpoint
India's Cigarettes and Other Tobacco Products Act (COTPA), 2003, prohibits direct advertising, sponsorship and promotion of tobacco products. Regulators have progressively widened the net, treating indirect promotion as a violation of the same intent.
The FDA's action against three high-profile actors signals that celebrities can no longer claim ignorance of what an ad campaign actually represents. A notice to a star of SRK's stature is not merely an administrative step — it is a warning to the entire endorsement industry.
How the Pan Masala Ad Row Built Up
Pan masala sits in a complicated regulatory space. Many variants contain tobacco, and nicotine-laced versions have been banned in several states. Advertisements for such products, direct or indirect, have drawn repeated caution from health regulators.
This is not the first time the spotlight has fallen on celebrities in this context. In recent years, government agencies and advertising watchdogs have repeatedly flagged the use of familiar faces to promote tobacco-adjacent products while bypassing ad bans.
What the FDA Is Asking the Three Stars
According to the reported development, the actors have been asked to clarify their participation in the campaign. Whether they were paid endorsers, appeared as part of creative direction, or were unaware of the product linkage — this is now for them to establish.
No official response from the actors or their teams has been reported in the available information so far.
Why This Matters to Fans and Consumers
For the public, this is more than a celebrity controversy. Surrogate advertising works precisely because familiar faces build trust in a brand name. When a consumer picks up a product endorsed by a beloved actor, they rarely pause to ask what the brand truly sells.
Public health advocates argue that such promotions normalise tobacco consumption among younger audiences. The FDA's notices, therefore, carry a public health weight far beyond the legal paperwork.
The Official Position and the Road Ahead
The Maharashtra FDA has positioned the action as part of its broader commitment to checking illegal tobacco marketing. Formal notices are typically a precursor to further inquiry — the regulator can seek documents, summon representatives, or escalate the matter if responses are unsatisfactory.
What happens next depends largely on the replies the regulator receives from the three actors.
Behind the Crackdown: A Pattern of Heightened Scrutiny
The notices fit into a larger shift. Advertising Standards Council of India (ASCI) guidelines and government advisories have repeatedly flagged surrogate ads as a violation of consumer protection norms. Regulators are now moving from advisories to enforcement.
Celebrities are being repositioned from mere faces of brands to accountable parties in marketing compliance. For an endorsement-heavy industry like Bollywood, this is a structural change.
Confirmed So Far vs What Remains Unclear
What is confirmed in the reported development: the Maharashtra FDA issued formal notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff; the allegation concerns surrogate advertising linked to a banned pan masala product; and the actors must clarify their role in the campaign.
What remains unclear: whether the actors have responded, which specific brand is at the centre of the inquiry, and whether any financial penalty is being considered. No independent or official source documents were available at the time of writing beyond the headline development. All references to possible legal action are speculative.
The Celebrity Endorsement Dilemma: Reputation vs Responsibility
An actor's brand is their most valuable asset. A legal notice of this kind can trigger questions about due diligence in endorsement contracts, potentially affecting future brand associations and endorsement fees.
At the same time, the case exposes the uncomfortable mechanics of celebrity marketing — how far can a face go before it becomes responsible for the product it implicitly promotes?
The Other Side: Risks and Open Questions
Not everyone will read this as a clear-cut violation. Defenders of the actors may argue that creative teams and advertising agencies design campaigns, while celebrities often appear in ads based on briefs that may not disclose the full commercial intent.
There is also a question of consistency. Many brands continue to advertise in near-identical formats across media without facing action, raising concerns about selective enforcement.
Wider Trend: Regulators Moving Against Celebrity-Fronted 'Dark Patterns'
From misleading health products to
